Cholinomimetic drugs, also known as parasympathomimetics or cholinergic agonists, increase acetylcholine (ACh), which acts on cholinergic muscarinic and nicotinic receptors. Other cholinomimetic drugs result in a net cholinergic effect by inhibiting the cholinesterase enzyme. Muscarinic receptors are found in the CNS and are part of the parasympathetic nervous system, which responds to cholinomimetics. Nicotinic receptors are found in the CNS at the neuromuscular junction. Physiologic effects on muscarinic receptors include bronchoconstriction, lacrimation, and bradycardia. Physiologic effects on nicotinic receptors include vasoconstriction, tachycardia, and elevated blood pressure. Cholinergic activation of muscarinic receptors on vascular endothelial cells cause an increase in nitric oxide, which diffuses to the adjacent vascular smooth muscle cells, resulting in smooth muscle relaxation/vasodilation and a paradoxical effect of the cholinomimetics on bronchial smooth muscle (constriction) and vascular smooth muscle (relaxation). Clinical uses of cholinomimetic agents include treatment of dementia, glaucoma, and as an aid for smoking cessation. The primary adverse effect of cholinergic drugs is overstimulation of the parasympathetic nervous system. Symptoms result from excessive levels of ACh in synapses, glands, smooth muscles, and motor endplates.